Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Elanco Animal Health Incorporated (NYSE: ELAN) SEC filings page on Stock Titan provides organized access to the company’s U.S. regulatory disclosures. As an Indiana-incorporated public company in the pharmaceutical preparation manufacturing industry, Elanco files reports with the Securities and Exchange Commission under Commission File Number 001-38661.
Through this page, readers can review current and historical Forms 8-K and, when available, annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy materials. Elanco’s recent Form 8-K filings illustrate the range of topics covered in its SEC disclosures, including quarterly financial results and guidance, restructuring plans and workforce changes, amendments to credit agreements and receivables facilities, and participation in major investor events such as its Investor Day and healthcare conferences.
These filings provide detail on Elanco’s financial condition, capital structure and risk factors, as well as material contracts and strategic initiatives. For example, recent 8-Ks describe the Elanco Ascend restructuring program, expected cost savings, facility changes, and refinancing of term loan facilities, along with updates on leverage targets and cash flow expectations. Other filings outline amendments to securitization and credit agreements that affect the company’s direct financial obligations.
Stock Titan enhances this information with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the significance of each filing. Investors can use the ELAN filings page to monitor new 8-Ks, as well as future 10-K and 10-Q reports, and to track how management’s strategic, financial and operational decisions are reflected in official SEC documents.
Elanco Animal Health reported that officer Rajeev A. Modi acquired a grant of 56.6301 deferred stock units on Company stock, valued at $24.98 per unit. After this award, his direct holdings in these deferred stock units total 7,651.0914 units.
Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent. According to the company’s Executive Deferral and Stock Match Plan, these units are scheduled to settle in cash or shares after employment ends or in a specified future year.
Elanco Animal Health President and CEO Jeffrey N. Simmons reported an acquisition of deferred stock units as part of his compensation. He received 110.8583 deferred stock units on Company common stock at a reference price of $24.98 per unit, described as a grant or award. After this award, his direct holdings of deferred stock units total 19,179.7639 units. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, and they settle in cash or shares following termination of employment or in a specified future year under the Executive Deferral and Stock Match Plan.
VanHimbergen Robert M reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen received a grant of 7.6217 deferred stock units at a reference price of $24.98 per unit. This award increases his directly held deferred stock units to 31.0919. Each unit represents the right to receive one share of Elanco common stock or the cash equivalent, settling after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health Incorporated provides its annual report for the year ended December 31, 2025, detailing its global animal health business focused on pet and farm animal products sold in more than 90 countries. The company highlights a diversified portfolio where its top five product families, including Advantage, Seresto, Credelio, Rumensin and Maxiban/Monteban, contribute about 38% of total revenue, with Advantage alone at roughly 10%. Elanco reports significant innovation efforts, with recent approvals and launches such as Bovaer for methane reduction in dairy cattle, Zenrelia and Credelio Quattro for dogs, and Befrena, an anti-IL31 monoclonal antibody for canine dermatitis expected to launch in 2026. R&D expense was $368 million in 2025, supported by over 1,000 R&D and regulatory employees and a global network of centers. The company describes a major restructuring plan approved in December 2025 that includes $155 million of charges in 2025, planned site closures in Germany and Kansas, and an expected net headcount reduction of about 300 employees. Elanco also outlines extensive regulatory, manufacturing, IT, climate and market risks, including patent expirations, generic competition, antibiotic usage pressures and shifting distribution toward e‑commerce.
Elanco Animal Health reported strong growth for the fourth quarter of 2025, with revenue of $1,144 million, up 12% on a reported basis and 9% in organic constant currency. Pet Health and Farm Animal both grew double digits, helped by new products like Credelio Quattro, Zenrelia and Experior.
For full year 2025, revenue rose 6% to $4,715 million and organic constant currency growth was 7%. Despite this, Elanco posted a reported net loss of $232 million, largely reflecting amortization and restructuring, while adjusted net income was $473 million and adjusted EBITDA was $901 million, a 19.2% margin.
The company issued 2026 guidance for revenue of $4,950–$5,020 million, implying 4%–6% organic constant currency growth, adjusted EBITDA of $955–$985 million and adjusted EPS of $1.00–$1.06. Elanco raised its 2026 innovation revenue target to $1.15 billion and targets a year-end net leverage ratio of 3.1x–3.3x, down from 3.6x at December 31, 2025.
Dodge & Cox filed an amended Schedule 13G reporting a large passive ownership stake in Elanco Animal Health Incorporated. The firm beneficially owns 79,084,305 Elanco common shares, representing 15.9% of the class, with sole voting power over 75,198,905 shares and sole dispositive power over the full 79,084,305 shares.
The filing notes that Dodge & Cox’s clients, including registered investment companies and other managed accounts, have the right to receive dividends and sale proceeds from these securities. The Dodge & Cox Stock Fund alone holds 53,122,900 Elanco shares, or 10.7% of the class. Dodge & Cox certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Elanco.
Elanco Animal Health executive Robert M. VanHimbergen, EVP and CFO, reported a compensation-related grant of deferred stock units. On 02/06/2026 he acquired 7.5552 deferred stock units at $25.2 each, bringing his beneficially owned deferred stock units to 23.4702.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. These units settle in cash or shares after termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health Inc. reported an insider equity award for its President, CEO and Director, Jeffrey N. Simmons, on February 6, 2026. He acquired 109.8905 deferred stock units at $25.2 per unit, bringing his directly held deferred stock units to 19,068.9056.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. These units settle in cash or shares after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health executive Rajeev A. Modi reported a routine equity award. On February 6, 2026, he acquired 56.1357 deferred stock units at a reference price of
Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent. These units settle in cash or shares after termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
FMR LLC has filed an amended Schedule 13G indicating beneficial ownership of 52,196,321.38 shares of Elanco Animal Health Inc. common stock, representing 10.5% of the class. FMR reports sole voting power over 44,813,598.91 shares and sole dispositive power over 52,196,321.38 shares.
Abigail P. Johnson is also listed as a reporting person with sole dispositive power over the same 52,196,321.38 shares and no voting power. The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Elanco.